Stocks Health care REGN
NASDAQ · Health careRegeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. brought in $15.5B of revenue over the twelve months to June 30, 2026, up 9.3% from a year earlier. Net income was $4.3B, a net margin of 27.9%. Operating cash flow minus capital spending left $4.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $2.5B in cash against $2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Regeneron Pharmaceuticals, Inc. does
Regeneron Pharmaceuticals discovers, develops, and manufactures medicines for people with serious diseases. Its products treat conditions such as eye diseases, allergic and inflammatory conditions, cancer, and cardiovascular disease. The company sells its prescription drugs to healthcare providers, pharmacies, and distributors. Its shares trade on NASDAQ under the ticker REGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.3B | $4.5B | $41.48 | $4.1B |
| 2024 | $14.2B | $4.4B | $38.34 | $3.7B |
| 2023 | $13.1B | $4B | $34.77 | $3.9B |
| 2022 | $12.2B | $4.3B | $38.22 | $4.4B |
| 2021 | $16.1B | $8.1B | $71.97 | $6.5B |
| 2020 | $8.5B | $3.5B | $30.52 | $2B |
Where REGN ranks in Health care
Dividends
It paid out $370.3M in cash dividends, 8% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $370.3M | 8% |
| 2024 | n/a | $0 | 0% |
| 2023 | n/a | $0 | 0% |
Latest SEC filings
What Regeneron Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 20, 2026Form N-PX filing N-PX
- August 7, 2026Form 13F-HR filing 13F-HR
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- July 6, 2026
- June 17, 2026
- May 8, 2026Form 13F-HR filing 13F-HR
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
- April 29, 2026Quarterly report 10-Q · period to March 31, 2026
- April 29, 2026
What is REGN worth? A DCF from its reported cash flow
Insider trades
What the people running Regeneron Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | McCourt MarionEVP Commercial | Soldpre-planned (10b5-1) | 1,131 | $969.7K |
| September 2, 2026 | McCourt MarionEVP Commercial | Soldpre-planned (10b5-1) | 1,215 | $1M |
| September 2, 2026 | Guarini KathrynDirector | Exercised options | 400 | $287.7K |
| September 2, 2026 | Guarini KathrynDirector | Soldpre-planned (10b5-1) | 400 | $340K |
Questions about REGN
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals discovers, develops, and manufactures medicines for people with serious diseases. Its products treat conditions such as eye diseases, allergic and inflammatory conditions, cancer, and cardiovascular disease. The company sells its prescription drugs to healthcare providers, pharmacies, and distributors. Its shares trade on NASDAQ under the ticker REGN.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $4.3B on revenue of $15.5B, a net margin of 27.9%.
How much revenue does Regeneron Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Regeneron Pharmaceuticals, Inc. reported revenue of $15.5B. That is 9.3% more than a year earlier.
When did Regeneron Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Compare REGN with
Follow REGN
Get an email when Regeneron Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow REGN: get an email when it filesWhere the numbers come from
Financial figures are the values Regeneron Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.